Profile Response Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

Molecular Profile Unknown unknown
Therapy Toripalimab
Indication/Tumor Type Advanced Solid Tumor
Response Type not applicable


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown Advanced Solid Tumor not applicable Toripalimab Phase I Actionable In a Phase I trial, Toripalimab (JS001) demonstrated tolerability and preliminary efficacy in patients with advanced malignancies, resulting in an objective response rate of 45.5% (15/33), including complete response in 7/33, partial response in 8/33, and stable disease in 13/33 patients, and median progression-free survival of 7.1 months, with solid tumor patients demonstrating an objective response rate of 22.7% (5/22) and median progression-free survival of 5.7 months (PMID: 32224416; NCT02836834). 32224416
PubMed Id Reference Title Details
(32224416) Safety and clinical efficacy of toripalimab, a PD-1 mAb, in patients with advanced or recurrent malignancies in a phase I study. Full reference...